EUCTR2009-017141-58-IT进行中（未招募）不适用
An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 to 60 Years. - ND
OPERA SR0 个研究点开始时间: 2009年11月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent obtained; 2. Males and females from 18 years to 60 years of age on the day of enrolment; 3. Subjects in good health as determined by the outcome of medical history, physical assessment and clinical judgment by the Investigator; 4. Subjects are able to comply with all study procedures and are available for all clinic visits scheduled in the study; 5. Willingness to allow for blood samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who are not able to comprehend and to follow all required study procedures for the whole period of the study; 2. Subjects with history or any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study; 3. Subjects with any serious chronic or progressive disease according to judgment of the Investigator (including, but not limited to malignant neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease); 4. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, to any excipients, and to eggs (including ovalbumin), and chicken proteins; 5. Subjects who have had seasonal influenza vaccine or documented confirmed seasonal influenza disease within 2 weeks prior to Day 1; 6. Receipt of another investigational agent within 4 weeks prior to enrolment, or before completion of the safety follow-up period in this or in another study; subjects unwilling to refuse participation in another clinical study throughout the end of this study; 7. Subjects who received any other vaccines within 4 weeks prior to enrolment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines; the only exception being plain seasonal influenza vaccines which are allowed until 2 weeks before and over 2 weeks after the study vaccination; 8. Subjects who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks or plan to receive these products during the full length of the study; 9. Subjects with axillary temperature ≥ 38C (≥ 100.4F) or oral temperature ≥ 38.5C (≥ 101.3F) within 3 days of intended study vaccination; 10. Known or suspected impairment/alteration of immune function, for example resulting from: a. receipt of immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis (10 mg/day of prednisone or its equivalent) or chronic use of inhaled high-potency corticosteroids (e.g. budesonide 800?g/day or fluticasone 750?g/day) within 60 days prior to Visit 1, b. cancer chemotherapy within 5 years, c. receipt of immunostimulants within 60 days prior to Visit 1, d. history of HIV infection or HIV-related disease; 11. History of progressive or severe neurological disorders (including Guillain-Barre` syndrome and convulsions, but excluding febrile convulsions); 12. History of or clinically suspected developmental delay; 13. Bleeding diathesis; 14. Surgery planned during the study period that in the Investigator s opinion would interfere with the study; 15. Female subjects who are pregnant or nursing (breastfeeding) mothers, or females of childbearing potential who are sexually active and have not used any of the acceptable contraceptive methods for the 2 months before entering the study or do not plan to use them up to the end of the study; 16. Members of the research staff who have direct access to any study documents containing subject information.
研究者
相似试验
尚未招募
3 期
Treatment of Irq-Un-Nisa (Sciatica) with Unani medicine Habb-e-Irq-un-NisaCTRI/2022/01/039133Central Council for Research in Unani Medicine CCRUM New Delhi
尚未招募
3 期
Treatment of Nisyan (Amnesia) with Unani medicine Majun BoolusCTRI/2021/07/034593Central Council for Research in Unani Medicine CCRUM New Delhi
尚未招募
3 期
Treatment of difficulty or trouble in breathing with Unani medicine Laooq-e-HulbaCTRI/2023/04/051554Central Council for Research in Unani Medicine CCRUM New Delhi
尚未招募
3 期
Treatment of Ringworm infection with Unani medicines Qurs Asfar and Roghan NarjeelCTRI/2021/05/033851Central Council for Research in Unani Medicine CCRUM New Delhi
尚未招募
3 期
Treatment of fever (Humma) with Unani medicine Habb-e-KaranjawaCTRI/2021/09/037012Central Council for Research in Unani Medicine CCRUM New Delhi